Literature DB >> 14615466

Considerations in analyzing single-trough concentrations using mixed-effects modeling.

Brian P Booth1, Jogarao V S Gobburu.   

Abstract

The purpose of this study was to assess the effect of trial design and data analysis choices on the bias and precision of pharmacokinetic (PK) parameter estimation. NONMEM was used to simulate and analyze plasma concentrations collected according to a dense (five samples) or sparse (single-trough samples) sampling scheme for a one-compartment open model with intravenous administration. The results indicated that the bias on estimates of CL with only single-trough data was 17% compared to less than 1% for only dense data. The estimates of CL were improved by fixing all other parameters and estimating only mean and variance of CL (-11% to 1.4%, depending on the estimation method). Adding dense data led to further improvements (-2.3% to 0.3%, depending on further improvements). In these cases, first-order conditional estimation (FOCE) methods resulted in better estimates of CL than first-order (FO) methods. These steps also improved the Bayesian estimates of CL. These studies support the following recommendations: (1) avoid collecting single-trough concentrations unless there is reasonable knowledge about the PK of the drug; (2) if collecting single-trough concentrations is inevitable, avoid estimating all parameters when modeling single-trough concentration data; (3) use prior information by modeling the single-trough concentration data along with dense data from other studies; and (4) use Bayes estimates if the PK model and its parameters are known with reasonable certainty.

Mesh:

Year:  2003        PMID: 14615466     DOI: 10.1177/0091270003258670

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

Authors:  Andrew C Hooker; Christine E Staatz; Mats O Karlsson
Journal:  Pharm Res       Date:  2007-07-06       Impact factor: 4.200

2.  The underlying inflammatory chronic disease influences infliximab pharmacokinetics.

Authors:  Christophe Passot; Denis Mulleman; Theodora Bejan-Angoulvant; Alexandre Aubourg; Stephanie Willot; Thierry Lecomte; Laurence Picon; Philippe Goupille; Gilles Paintaud; David Ternant
Journal:  MAbs       Date:  2016-08-09       Impact factor: 5.857

3.  Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

Authors:  Dara J Sakolsky; James M Perel; Graham J Emslie; Gregory N Clarke; Karen Dineen Wagner; Benedetto Vitiello; Martin B Keller; Boris Birmaher; Joan Rosenbaum Asarnow; Neal D Ryan; James T McCracken; Michael J Strober; Satish Iyengar; Giovanna Porta; David A Brent
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

4.  Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.

Authors:  Katarina Vučićević; Marija Jovanović; Bojana Golubović; Sandra Vezmar Kovačević; Branislava Miljković; Žarko Martinović; Milica Prostran
Journal:  Eur J Clin Pharmacol       Date:  2014-11-09       Impact factor: 2.953

5.  Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Giovanni B Cassano; Paola Rucci; Daniel J Müller; James L Kennedy; Rocco Nicola Forgione; Margaret Kirshner; Gail Kepple; Andrea Fagiolini; David J Kupfer; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

6.  Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.

Authors:  Noppaket Singkham; Somchai Towanabut; Surang Lertkachatarn; Baralee Punyawudho
Journal:  Eur J Clin Pharmacol       Date:  2012-12-21       Impact factor: 2.953

7.  Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Authors:  Nyein Hsu Maung; Janthima Methaneethorn; Thitima Wattanavijitkul; Tatta Sriboonruang
Journal:  Eur J Hosp Pharm       Date:  2021-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.